NY-SURESCAN
SureScan Corporation, an emerging leader bringing advanced technology and manufacturing to the homeland security marketplace, today announced that its x 1000 checked baggage screening solution has successfully achieved European Civil Aviation Conference’s (ECAC) Explosive Detection System (EDS) Standard 3. The SureScan x 1000 was the first multi-energy stationary gantry CT EDS to be TSA certified, and is now ECAC EDS Standard 3.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151116006649/en/
“We have engineered a solution that is future proof and operates at a much lower life cycle cost compared to those installed in airports,” said LeeAnn Levesque, President and CEO of SureScan. “Obtaining ECAC EDS Standard 3 positions the SureScan x 1000 as the most comprehensive, next-generation solution for airports and their stakeholders, realizing considerable savings year-over-year.”
The SureScan x 1000 next-generation CT EDS solution is:
- Built from the ground up for checked baggage screening in an airport environment vs. inferior solutions adapted from less demanding medical applications.
- Flexible and future proof, engineered for simple field software upgrades for emerging threat detection and higher belt speeds forever increasing and faster passenger baggage throughput.
- The most cost effective solution available with reduced power consumption, cooling efficiencies, self-calibration and a stationary gantry with no moving parts.
- CT technology enhanced with multi-energy detection for atomic number analysis enabling the x 1000 to detect threats at a low false alarm rate, today and into the future.
- Screens large bags with a rectangular tunnel throughout providing jam-free, continuous operation and faster throughput.
To learn more visit www.surescaneds.com
About SureScan™ Corporation
SureScan Corporation is an emerging leader in explosives detection servicing the U.S. and international markets with corporate offices in Endicott, NY. SureScan is dedicated to developing and manufacturing solutions to enhance national and international security by combining advanced technology with world-class production and value engineering expertise.
Focusing on the needs of stakeholders in the homeland security marketplace, SureScan strives to provide effective and economical solutions, knowing critical security issues must be addressed without dismissing financial realities. This pragmatic approach results in solutions that are efficient, cost-effective and meet rigorous detection and quality standards.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151116006649/en/
Contact:
SureScan Corporation
Susan Cooper, +1-973-830-6798
susan.cooper@surescaneds.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker kapaciteten med samarbejdsfirmaet Market One30.6.2025 01:12:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter udvidelsen af sin globale platform gennem en samarbejdsaftale med Market One, et konsulentfirma med base i Argentina, der specialiserer sig i kommercielle end-to-end-løsninger. Market One har hovedkontor i Argentina og er et førende konsulentfirma med speciale i kommerciel transformation i alle processens faser. Firmaet blev stiftet i 2009 af partnerne Esteban Neville og Jerónimo Fernández Abeijón og har en praktisk, resultatorienteret tilgang til alle projekter – de følger kunderne fra strategi til udførelse. Ekspertisen spænder over strategisk rådgivning, kommerciel optimering, teknologiaktivering og indsigtsdrevet beslutningstagning. Med en dokumenteret erfaring fra over 1.200 projekter i mere end 20 lande arbejder Market One med nogle af de mest anerkendte brands i verden og hjælper dem med at styrke deres kommercielle kapacitet og opnå bæredygtig vækst. "Vi er født til at løse problemer, men det er måden, vi gør det på, der adskiller os fra andre," s
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom